Anti-tumor efficacy of theliatinib in esophageal cancer patient-derived xenografts models with epidermal growth factor receptor (EGFR) overexpression and gene amplification
Metrics: PDF 950 views | HTML 1239 views | ?
Yongxin Ren1,*, Jianming Zheng2,*, Shiming Fan1,*, Linfang Wang1, Min Cheng1, Dongxia Shi1, Wei Zhang1, Renxiang Tang1, Ying Yu1, Longxian Jiao1, Jun Ni1, Haibin Yang3, Huaqing Cai3, Fang Yin1, Yunxin Chen1, Feng Zhou1, Weihan Zhang3, Weiguo Qing1 and Weiguo Su3
1Department of Oncology Research, Hutchison MediPharma Limited, Shanghai, China
2Department of Pathology, Changhai Hospital, the Second Military Medical University, Shanghai, China
3Department of Chemistry, Hutchison MediPharma Limited, Shanghai, China
*These authors are contributed equally to this work
Yongxin Ren, email: email@example.com
Weiguo Su, email: firstname.lastname@example.org
Keywords: esophageal cancer, patient derived xenograft models, EGFR targeted therapy, theliatinib
Received: December 01, 2016 Accepted: March 27, 2017 Published: April 19, 2017
Targeted therapy is not yet approved for esophageal cancer (EC). In this study, we first evaluated EGFR gene and protein expression in 70 Chinese EC patient tumor samples collected during surgery. We then established 23 patient-derived EC xenograft (PDECX) models and assessed the efficacy of theliatinib, a potent and highly selective EGFR inhibitor currently in Phase I clinical study, in 9 PDECX models exhibiting various EGFR expression levels. Immunohistochemical analysis showed that 50 patient tumor samples (71.4%) had high EGFR expression. Quantitative PCR showed that eight tumors (11.6%) had EGFR gene copy number gain, and fluorescence in situ hybridization (FISH) revealed that four tumors had EGFR gene amplification. These results suggest that EGFR protein may be overexpressed in many EC tumors without gene amplification. Also detected were rare hot-spot mutations in EGFR and PIK3CA, whereas no mutations were found in K-Ras or B-Raf. Theliatinib exhibited strong antitumor activity in PDECX models with high EGFR expression, including remarkable tumor regression in two PDECX models with both EGFR gene amplification and protein overexpression. However, the efficacy of theliatinib was diminished in models with PI3KCA mutations or FGFR1 overexpression in addition to high EGFR expression. This study demonstrates that theliatinib could potentially benefit EC patients with high EGFR protein expression without mutations or aberrant activities of associated factors, such as PI3KCA or FGFR1.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.